Opinion|Videos|May 1, 2026
Personalizing Long-Term Treatment of Metastatic Castration-Sensitive Prostate Cancer
Fact checked by: Tracy Ann Politowicz
This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.
Episodes in this series
This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5